Last reviewed · How we verify
NCT05562713
CIC Behavioral Economics in Children With Spina Bifida
NA trial testing Present Bias without Loss Aversion in Spina Bifida in 22 participants. Completed in 18 April 2024.
18 April 2024
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 22 |
| Start date | 1 August 2023 |
| Primary completion | 18 April 2024 |
| Estimated completion | 18 April 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Present Bias without Loss Aversion
- Present Bias with Loss Aversion
Conditions studied
- Spina Bifida — all drugs for Spina Bifida →
- Neurogenic Bladder — all drugs for Neurogenic Bladder →
Sponsor
Duke University
Who can join
Adults 4 to 12, any sex, with Spina Bifida or Neurogenic Bladder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to develop a comprehensive program to increase early initiation of self-catheterization in children with Spina Bifida. This will be a prospective open label randomized control trial. Patients and caregivers/guardians in the intervention arm will be enrolled in a comprehensive program that utilizes behavioral economic theory to incentivize initiation of independent CIC. The study population will be patients aged 4 to 12 years old with diagnosis of spina bifida, including meningocele and myelomeningocele, as defined by International Classification of Diseases, 10th revision (ICD10). This study will look at behavioral interventions. There are no additional physical risks to participation in the study. Patient demographics will be reported using descriptive statistics. Study team will use Kaplan-Meier curves to demonstrate and compare the probability of achieving independent CIC over time between the study arms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05562713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spina Bifida
Currently open trials in the same condition.
- NCT06723951 — QUALAS Validation in Dutch · recruiting
- NCT06041334 — Evaluation of muLtimodal and Non-invasive SPINa Bifida Neurovessels During Prospective Follow-up · NA · recruiting
- NCT06802770 — Evaluation of Depression and Anxiety Levels of Parents of Children with Spina Bifida · active not recruiting
- NCT05726591 — Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Dis · NA · recruiting
- NCT05339932 — Grand Valley State University (GVSU) Skills on Wheels · NA · active not recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05562713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 6 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05562713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing